Once all plates have been washed with block added into the wells and returned to the output stack, all plates are then restacked into the original order into the input stack. It is necessary to clean the syringe B dispense head and line soon after the block has been added to all plates to prevent clogging of the dispense LUF6000 tips. patient samples serve as positive controls. Using this protocol, minimal cross-reactivity is observed for the spike proteins of MERS, SARS1, OC43 and HKU1 viruses, and no cross reactivity is observed with anti-influenza A H1N1 HAI. Our protocol may thus help provide standardized, population-based data on the extent of SARS-CoV-2 seropositivity, immunity and infection. Subject terms: ELISA, Antibodies, Viral infection, Laboratory techniques and procedures Understanding the infection parameters and host responses against SARS-CoV-2 require data from large cohorts using standardized methods. Here, the authors optimize a serum ELISA protocol that has minimal cross-reactivity and flexible sample collection workflow in an attempt to standardize data generation and help inform on COVID-19 pandemic and immunity. Introduction SARS-CoV-2 has spread across the globe rapidly, causing a worldwide pandemic1. Infection with this highly contagious respiratory virus can be asymptomatic or present as COVID19, a disease with varying levels of severity and a broad range of not fully understood symptoms that may include fever, cough, anosmia, gastrointestinal symptoms, hypercoagulability, inflammatory complications, acute respiratory distress syndrome, which may also lead to death2C5. Owing to the rapidly evolving nature of pandemics, the true extent of spread of SARS-CoV-2 will likely not be fully realized until late inCor even afterthe pandemic. Moreover, as observed in all respiratory viral pandemics since 1918, the true number of infections always exceeds the detected cases6,7. In order to determine a better estimate of the prevalence of SARS-CoV-2 infection, high-quality serology assays must be developed. These assays measure the presence of antibodies against LUF6000 specific proteins of this novel coronavirus (to determine whether an individual has been infected with SARS-CoV-2) and aim for high sensitivity and specificity8,9. Both are important factors to diagnose prior infection; however, if a tradeoff between sensitivity and specificity is needed, high specificity should be emphasized when determining the extent of exposure across a population or for diagnosing previous infections. If such a highly specific, high-quality assay is available, then data can be generated from serosurveys and clinical testing that LUF6000 can be used to better understand the spread of infection, immunity, and correlates of protection. Owing to the complex nature of immune responses and the temporal changes associated with canonical responses to infection10C12, a combination of proper technical validity and proper interpretation of results is critical for understanding the meaning of the data acquired during serostudies. Earlier studies have shown differing dynamics of antibodies, suggesting an important need for utilization of multiple antigens or multiple assays to properly measure seropositivity. More specifically, a degradation of anti-nucleocapsid titers has been reported, whereas anti-Spike antibodies appear to persist for a longer duration13,14. Furthermore, particular specific antibodies, such as those against the receptor-binding website (RBD) of SARS-CoV-2 spike, can correlate well with neutralization15, which has also been demonstrated for the original SARS-CoV16, though it may miss a polyclonal response as non-RBD binding neutralizing antibodies have been reported17,18. Here, we present an optimized enzyme-linked immunosorbent assays (ELISA)-centered serology assay protocolfrom protein production to data analysisthat analyzes the presence of IgG, IgM, and IgA antibodies against spike and RBD antigens of SARS-CoV-2. We also demonstrate how our screening protocol can be validated and how specific thresholds for positivity can be arranged for manual and semi-automated methods. Evaluation of all guidelines of serologic assays, such as those in the workflow offered here, is critical for appropriate interpretation of antibody screening both in medical and general public health applications. Results In order to properly prepare to generate such useful data from a now-ongoing National Institutes of Health (NIH) sponsored national serosurvey in the United States (NCT04334954), we developed a serology protocol that emphasizes specificity while keeping a simple approach that can be repeated at relatively low cost in laboratories without specialised equipment. The NIH serosurvey study allows mail-in home sampling using dried blood on a microsampler or collection of blood on-site. Therefore, we developed, implemented, and evaluated a serology screening protocol using ELISA that could successfully be used with multiple sample types, while emphasizing LUF6000 the specificity required to conduct high-quality convalescent screening and serosurveys (Fig.?1). Open in a separate windowpane Fig. 1 Serology screening protocol for evaluation of SARS-CoV-2 seropositivity inside a large-scale human population.Utilizing both Nr4a3 venipuncture-derived fresh blood and dried blood spots, we have standardized a dual-antigen ELISA platform for highly specific (IgG?=?100%, 95% confidence interval?=?98.5C100) detection of SARS-CoV-2 antibodies for software in precise, large-scale.